You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 10, 2025

Valeant Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Valeant
International Patents:44
US Patents:6
Tradenames:58
Ingredients:48
NDAs:74
Patent Litigation for Valeant: See patent lawsuits for Valeant

Drugs and US Patents for Valeant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharm Intl PREDNISONE prednisone TABLET;ORAL 080237-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free
Valeant Pharm Intl LIBRIUM chlordiazepoxide hydrochloride CAPSULE;ORAL 012249-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
Valeant Pharms Intl GIAZO balsalazide disodium TABLET;ORAL 022205-001 Feb 3, 2012 DISCN Yes No 7,452,872 ⤷  Try for Free ⤷  Try for Free
Valeant Bermuda DERMATOP E EMOLLIENT prednicarbate CREAM;TOPICAL 020279-001 Oct 29, 1993 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
Valeant Pharm Intl SECOBARBITAL SODIUM secobarbital sodium CAPSULE;ORAL 085477-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free
Valeant Bermuda RETIN-A tretinoin CREAM;TOPICAL 017522-001 Approved Prior to Jan 1, 1982 AB1 RX Yes Yes ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Valeant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharm Intl PERMAX pergolide mesylate TABLET;ORAL 019385-001 Dec 30, 1988 4,797,405 ⤷  Try for Free
Valeant Pharms North RENOVA tretinoin CREAM;TOPICAL 021108-001 Aug 31, 2000 6,531,141 ⤷  Try for Free
Valeant Pharm Intl LIBRIUM chlordiazepoxide hydrochloride CAPSULE;ORAL 012249-002 Approved Prior to Jan 1, 1982 4,316,897 ⤷  Try for Free
Valeant Intl RETIN-A tretinoin GEL;TOPICAL 017579-002 Approved Prior to Jan 1, 1982 4,247,547 ⤷  Try for Free
Valeant Pharms North RENOVA tretinoin CREAM;TOPICAL 019963-001 Dec 29, 1995 4,423,041 ⤷  Try for Free
Valeant Bermuda DERMATOP E EMOLLIENT prednicarbate CREAM;TOPICAL 020279-001 Oct 29, 1993 4,242,334 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for VALEANT drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 100 mg ➤ Subscribe 2007-01-08
➤ Subscribe Extended-release Tablets 300 mg ➤ Subscribe 2007-09-25
➤ Subscribe Capsules 75 mg ➤ Subscribe 2011-06-06
➤ Subscribe Extended-release Tablets 200 mg ➤ Subscribe 2007-03-28
➤ Subscribe Tablets 1.1 g ➤ Subscribe 2013-11-05

Supplementary Protection Certificates for Valeant Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1613296 CR 2015 00042 Denmark ⤷  Try for Free PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226
0809498 SPC/GB10/012 United Kingdom ⤷  Try for Free PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
1586316 122011100019 Germany ⤷  Try for Free PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518
1458369 CA 2008 00029 Denmark ⤷  Try for Free PRODUCT NAME: ADAPALEN, BENZOYLPEROXID
3209302 11/2023 Austria ⤷  Try for Free PRODUCT NAME: KOMBINATION VON FOSLEVODOPA ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON UND FOSCARBIDOPA ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON; REGISTRATION NO/DATE: 141371 20220826
1539166 13C0062 France ⤷  Try for Free PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Valeant – Market Position, Strengths & Strategic Insights

Last updated: February 12, 2025

In the ever-evolving pharmaceutical industry, understanding the competitive landscape is crucial for success. Today, we'll dive deep into Valeant Pharmaceuticals, now known as Bausch Health Companies Inc., examining its market position, strengths, and strategic insights. This analysis will provide valuable information for industry professionals, investors, and anyone interested in the pharmaceutical sector.

The Rise and Fall of Valeant Pharmaceuticals

Valeant Pharmaceuticals, founded in 1959 as ICN Pharmaceuticals, underwent a significant transformation in the early 2000s. The company rebranded itself as Valeant in 2003, marking the beginning of a new era[1].

The Pearson Years: A Period of Rapid Growth

In 2008, Michael Pearson took the helm as CEO, ushering in a period of aggressive growth through acquisitions. Pearson's strategy was simple yet controversial: acquire smaller pharmaceutical companies, cut costs (especially in R&D), and increase drug prices[2].

"Valeant's business model is built around the acquisition of smaller pharmaceutical companies rather than through investing in research and development." - Harvard Business School[2]

This approach led to remarkable short-term success. Between 2008 and 2015, Valeant's stock price soared, making it one of the best-performing stocks in America during that period[4].

The Downfall: Controversies and Challenges

However, Valeant's aggressive strategy eventually backfired. In 2015, the company faced intense scrutiny over its pricing practices and accounting methods. Allegations of improper bookkeeping through its relationship with specialty pharmacy Philidor Rx Services led to a sharp decline in investor confidence[1].

Valeant's Market Position

Despite its challenges, Valeant (now Bausch Health) remains a significant player in the pharmaceutical industry. Let's examine its current market position.

Key Market Segments

Bausch Health operates in several key pharmaceutical segments:

  1. Dermatology
  2. Gastrointestinal disorders
  3. Eye health
  4. Neurology[1]

The company's diverse portfolio allows it to maintain a presence in multiple therapeutic areas, reducing its reliance on any single market segment.

Global Presence

Bausch Health has a strong international presence, with operations in North America, Europe, and emerging markets such as Asia, Latin America, and Africa[2]. This global footprint provides opportunities for growth and helps mitigate risks associated with individual markets.

Strengths and Competitive Advantages

Despite its tumultuous history, Bausch Health possesses several strengths that contribute to its competitive position.

Strong Brand Portfolio

The company owns Bausch & Lomb, a well-known supplier of eye health products[1]. This brand recognition gives Bausch Health a significant advantage in the ophthalmology market.

Efficient Acquisition Strategy

While controversial, Valeant's acquisition-driven growth strategy demonstrated the company's ability to identify and integrate valuable assets. This skill could prove useful in future strategic moves[2].

Diversified Product Line

Bausch Health's wide range of products across multiple therapeutic areas provides a degree of stability and reduces the impact of setbacks in any single market segment[1].

Strategic Insights and Future Outlook

As Bausch Health moves forward, several strategic considerations come into play.

Rebranding and Reputation Management

The company's decision to rebrand from Valeant to Bausch Health in 2018 was a clear attempt to distance itself from past controversies[1]. Continuing to rebuild trust and improve its reputation will be crucial for future success.

Balancing Growth and R&D Investment

While Valeant's low R&D investment strategy led to short-term gains, it's not sustainable in the long run. Bausch Health will need to find a balance between acquisitions and internal innovation to ensure long-term growth[2].

Leveraging Digital Health Technologies

As the healthcare industry increasingly embraces digital technologies, Bausch Health has an opportunity to integrate these innovations into its product offerings and operations.

Competitive Analysis: Valeant vs. Industry Leaders

To truly understand Valeant's position, we need to compare it to other major players in the pharmaceutical industry.

R&D Investment Comparison

Valeant's R&D spending has historically been much lower than industry averages. While the industry average is around 18% of sales, Valeant allocated only about 6% to R&D[4]. This stark difference highlights the company's unique approach to growth and innovation.

Acquisition Strategy

Unlike many traditional pharmaceutical companies that focus on internal R&D, Valeant's strategy centered on acquiring smaller companies with promising drugs. This approach allowed for rapid growth but also led to high levels of debt[2].

Pricing Strategies

Valeant's aggressive price increases on acquired drugs set it apart from many competitors. While this strategy initially boosted profits, it also attracted significant criticism and regulatory scrutiny[4].

Lessons from Valeant's Experience

Valeant's journey offers valuable lessons for other pharmaceutical companies and investors.

The Importance of Sustainable Growth

Valeant's rapid growth through acquisitions and price increases proved unsustainable. This underscores the importance of balanced, long-term strategies in the pharmaceutical industry.

Ethical Considerations in Pricing

The backlash against Valeant's pricing practices highlights the need for pharmaceutical companies to consider ethical implications and public perception when setting drug prices.

The Role of R&D in Long-term Success

While Valeant's low R&D investment strategy led to short-term gains, it may have compromised the company's long-term innovation potential. This serves as a reminder of the crucial role R&D plays in the pharmaceutical industry.

The Future of Bausch Health

As Bausch Health moves forward, several factors will influence its future success.

Debt Management

With over $30 billion in debt as of 2015[1], managing and reducing this financial burden will be crucial for the company's future growth and stability.

Rebuilding Trust

Regaining the trust of investors, healthcare professionals, and patients will be an ongoing challenge and priority for Bausch Health.

Balancing Acquisition and Innovation

Finding the right balance between strategic acquisitions and internal R&D investment will be key to sustainable growth.

Impact on the Pharmaceutical Industry

Valeant's rise and fall has had lasting impacts on the pharmaceutical industry as a whole.

Increased Scrutiny on Pricing Practices

The controversy surrounding Valeant's pricing strategies has led to increased public and regulatory scrutiny of drug pricing across the industry.

Reevaluation of Growth Strategies

Valeant's experience has prompted many pharmaceutical companies to reevaluate their growth strategies, with a renewed focus on sustainable, ethical practices.

Emphasis on Transparency

In the wake of Valeant's accounting controversies, there's been an increased emphasis on transparency in financial reporting and business practices within the industry.

Key Takeaways

  1. Valeant's aggressive acquisition and pricing strategy led to rapid growth but ultimately proved unsustainable.
  2. The company's rebranding as Bausch Health represents an attempt to distance itself from past controversies and rebuild its reputation.
  3. Bausch Health's diverse product portfolio and global presence provide a foundation for potential future growth.
  4. The company's experience highlights the importance of balancing short-term gains with long-term sustainability in the pharmaceutical industry.
  5. Valeant's journey has had lasting impacts on the industry, including increased scrutiny on pricing practices and a renewed focus on ethical business strategies.

FAQs

  1. What led to Valeant's rapid growth in the early 2010s? Valeant's growth was primarily driven by an aggressive acquisition strategy, coupled with significant price increases on acquired drugs and cost-cutting measures, particularly in R&D.

  2. Why did Valeant change its name to Bausch Health? The name change was part of an effort to distance the company from past controversies and rebuild its reputation under new leadership.

  3. How does Bausch Health's R&D investment compare to industry averages? Historically, Valeant's R&D investment was significantly lower than industry averages, at about 6% of sales compared to the industry average of 18%.

  4. What are the main challenges facing Bausch Health today? Key challenges include managing a high debt load, rebuilding trust with stakeholders, and finding a sustainable balance between acquisitions and internal innovation.

  5. How has Valeant's experience impacted the broader pharmaceutical industry? Valeant's story has led to increased scrutiny of drug pricing practices, a reevaluation of growth strategies in the industry, and a greater emphasis on transparency and ethical business practices.

Sources cited: [1] https://en.wikipedia.org/wiki/Bausch_Health [2] https://d3.harvard.edu/platform-rctom/submission/valeant-valiant-vendor-or-voracious-villain/ [4] https://www.transparently.ai/blog/the-valeant-scandal

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.